FDAnews
www.fdanews.com/articles/97885-takeda-8217-s-hypertension-treatment-enters-phase-ii-clinical-stage

Takeda’s Hypertension Treatment Enters Phase II Clinical Stage

August 31, 2007

Takeda Pharmaceutical announced that its investigational compound, TAK-536, has entered into Phase II clinical trials in Japan.

According to Tekeda, TAK-536 is an angiotensin receptor blocker (ARB) whose mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.

The company added that it expects TAK-536 to show stronger antihypertensive action, and also to have superior profile in improving the insulin resistance and renal protective action when compared with existing ARBs.